Home | Business News | Browse by Publication | M | M2 Presswire

Issues Updates for Millennium Pharmaceuticals, Inc.

Article Excerpt
M2 PRESSWIRE-31 May 2006-marketgainer.com: Issues Updates for Millennium Pharmaceuticals, Inc(C)1994-2006 M2 COMMUNICATIONS LTD

RDATE:31052006

Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. Today's activity on the Nasdaq exchange has brought Millennium Pharmaceuticals, Inc (NASDAQ:MLNM) to the attention of our research team. Our goal is to create a community of international investors who consistently and effectively capitalize on the enormous gains the small-cap Canadian and American exchanges offer.

Shares increase $.40 to a high of $8.54 on the Nasdaq Wednesday. Momentum comes as Millennium Pharmaceuticals, Inc. announced positive top-line results from the Company's randomized, double-blinded, placebo-controlled Phase II clinical trial of MLN1202, a novel humanized monoclonal antibody that specifically targets the CCR2 chemokine receptor, in patients at high risk for atherosclerotic cardiovascular disease. Preliminary analysis showed that MLN1202 was well tolerated and fully met its primary endpoint of a significant reduction in C-Reactive Protein (CRP) levels, an inflammatory biomarker associated with atherosclerosis, for months after a single dose of MLN1202. These results were statistically and clinically significant relative to the placebo control arm (p = 0.0275). No serious adverse events were observed in patients exposed to MLN1202. Trial results are expected to be submitted for...